Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Cedric Christophe Nasnas, Elias Jabbour, Fadi Haddad, Nicholas James Short, Walid Macaron, Marianne Zoghbi, Lewis Fady Nasr, Nitin Jain, Emmanuel Almanza, Koji Sasaki, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Guillermo Garcia-Manero, Tapan M. Kadia, Sa A Wang, Jovitta Jacob, Rebecca Garris, Susan M. O'Brien, Hagop M. Kantarjian
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379332746